An Open-label, Phase I Dose Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2017
At a glance
- Drugs M 8891 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors EMD Serono Research & Development Institute
- 15 Aug 2017 Status changed from not yet recruiting to recruiting.
- 04 Jul 2017 Planned End Date changed from 2 Aug 2018 to 18 Jan 2019.
- 04 Jul 2017 Planned primary completion date changed from 2 May 2018 to 18 Jan 2019.